Netarsudil Mesylate

AR-15512 is a transient receptor potential melastatin 8 (TRPM8) agonist, which was added to Alcon’s portfolio following the acquisition of Aerie Pharmaceuticals in November 2022. Image Credit: Rabizo Anatolii / Shutterstock. Switzerland-based Alcon’s dry eye disease drug AR-15512 achieved primary endpoints in two Phase III trials, COMET-2 and COMET-3. In light of the positive data, the company plans to file for a new drug application (NDA) for AR-15512 with the US Food and Drug Administration (FDA) in mid-2024, as per a 9 January press release. The vehicle-controlled Phase III COMET-2 (NCT05285644) and COMET-3 (NCT05360966) trials enrolled more than 930 patients, aged 30 years and older, with dry eye disease. The studies met their primary endpoints with a significant proportion of the patients in the treatment arm demonstrating at least a 10mm increase in unanaesthetised Schirmer’s score at day 14. An increase of 10mm or more in Schirmer’s score signifies normal tear production. The participants in the AR-15512 treatment arm also showed rapid onset and sustained tear production compared to the vehicle. The changes in tear production were observed on the first day and persisted for the whole 90-day study duration. Alcon noted that AR-15512 was well tolerated, with no serious ocular adverse events being reported during the trials. AR-15512 is a transient receptor potential melastatin 8 (TRPM8) agonist. TRPM8 is a cold-sensing receptor located in the cornea and eyelid and can potentially relieve symptoms of dry eye disease. It was added to Alcon’s portfolio following the $930m acquisition of Aerie Pharmaceuticals in November 2022. The acquisition also included marketed ophthalmic drugs such as Rocklatan, a netarsudil and latanoprost ophthalmic solution; and Rhopressa, a netarsudil ophthalmic solution. Both of these drugs are indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. The dry eye disease market is forecasted to generate $11.1bn in sales across the seven major markets in 2028, as per GlobalData analysis . GlobalData is the parent company of Pharmaceutical Technology . Another late-stage drug being developed as a treatment for dry eye disease is Aldeyra Therapeutics’ reproxalap. The drug had a mixed bag of results as it demonstrated significant improvement in the Schirmer test in both Phase III TRANQUILITY (NCT04674358)and TRANQUILITY-2 (NCT05062330) trials but failed to meet its primary endpoint of reduction in conjunctival redness in the Phase III TRANQUILITY trial. In November 2023, the FDA rejected the reproxalap’s NDA and requested additional data to show the drug’s efficacy.

AR-15512, a topical transient receptor potential melastatin 8 (TRPM8) agonist, is a first-in-class product candidate for the treatment of the signs and symptoms of dry eye disease In both pivotal efficacy and safety studies (COMET-2 and COMET-3), the primary endpoint was achieved (p <0.0001) Dry eye affects an estimated 38 million people in the U.S. and less than 10% of diagnosed patients are treated with a prescription product1 GENEVA--(BUSINESS WIRE)-- Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced positive topline results from the two pivotal Phase 3 clinical trials (COMET-2 and COMET-3) evaluating the efficacy and safety of AR-15512, a candidate treatment for the signs and symptoms of dry eye disease (DED). In both COMET-2 and COMET-3, which enrolled more than 930 dry eye subjects in total (randomized 1:1 to AR-15512 or vehicle control), the primary endpoint of the proportion of subjects with at least a 10-mm increase in unanesthetized Schirmer’s score (a measure of tear production) achieved statistical significance at Day 14 [p<0.0001]. These data are consistent with the proposed mechanism of action of AR-15512. “We are excited by AR-15512 as it has the potential to address the limitations of current dry eye prescription options and provide Eye Care Professionals (ECPs) and dry eye sufferers with a new and effective approach to the management of dry eye, a chronic and undertreated disease,” said David Endicott, CEO of Alcon. “AR-15512 is the first product candidate in our emerging ophthalmic pharmaceutical portfolio, representing our legacy of commitment to innovation in eye care.” AR-15512 represents an opportunity to bring relief to dry eye sufferers. While DED is one of the most common ocular disorders, affecting an estimated 38 million people in the U.S., only about 18 million are diagnosed and less than 10% of those diagnosed are treated with a prescription product. This represents the significant need for an effective chronic treatment that can provide rapid natural tear production.1 In these studies, additional data derived from secondary endpoints demonstrated the rapid onset and sustained tear production associated with AR-15512 compared to vehicle, as early as Day 1 and persistent to Day 90. Overall, AR-15512 was well tolerated and no serious ocular adverse events were reported. “A key gap in dry eye medications is rapid speed of onset,” said Edward Holland, MD, Professor of Ophthalmology at the University of Cincinnati, a key advisor on COMET-2 and -3 and Senior Scientific Advisor at Alcon. “AR-15512 demonstrated this important achievement in both pivotal efficacy and safety studies and it represents a first-in-class candidate for chronic dry eye.” AR-15512 is an investigational drug product that has not been submitted to the U.S. Food and Drug Administration (FDA) for approval and is not currently commercially available. Alcon anticipates filing the NDA for AR-15512 with FDA in mid-2024. Alcon's ophthalmic pharmaceutical portfolio currently includes Rocklatan®, Rhopressa®, Simbrinza®, Eysuvis®, and Inveltys®. About Dry Eye Dry eye disease is one of the most common ocular surface disorders, affecting an estimated 38 million adults in the United States and an estimated 719 million more adults globally.1 While once considered a disease of aging populations, modern advancements, such as prolonged digital screen time, have contributed to a significant rise in DED across age and gender.2 Many existing prescription options for dry eye disease are generally regarded by many eye care professionals and patients as inadequate due to low treatment efficacy, slow onset of action and/or poor tolerability.3 About Alcon Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people’s lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 25,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care. Learn more at . Cautionary Note Regarding Forward-looking Statements This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “commitment,” “look forward,” “maintain,” “plan,” “goal,” “seek,” “target,” “assume,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “will” and similar references to future periods. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties and risks that are difficult to predict. Some of these factors are discussed in our filings with the United States Securities and Exchange Commission, including our Form 20-F. Should one or more of these uncertainties or risks materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated. Therefore, you should not rely on any of these forward-looking statements. Forward-looking statements in this press release speak only as of the date they are made, and we assume no obligation to update forward-looking statements as a result of new information, future events or otherwise. References Market Scope 2023 Dry Eye Product Market Review; does not include OTC artificial tears and other Rx anti-inflammatory and tear stimulants. The Relationship Between Dry Eye Disease and Digital Screen Use - PMC (nih.gov) Improved Dry Eye Drugs for 2022 and Beyond; Connect with us on Facebook LinkedIn